Liu Yan, Chang Jun, Bai Li-Ding
Department of Gastroenterology, Hospital of Integrated Chinese and Western Medicine, Tianjin, Tianjin 300100, China.
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China.
World J Clin Cases. 2024 Apr 16;12(11):1996-1999. doi: 10.12998/wjcc.v12.i11.1996.
Diabetes comprises a group of metabolic diseases characterized by hyperglycemia stemming from various factors. Current diabetes management primarily focuses on blood glucose control, yet it is inherently progressive, necessitating increased reliance on exogenous blood glucose control methods over time. Therefore, there is an urgent need to explore novel intervention strategies addressing both diabetes and its complications. The human intestinal microbiota, often referred to as the "second genome", exhibits significant diversity and plays a pivotal role in insulin resistance, glucose and lipid metabolism, and inflammatory response. Notably, Li and Guo have elucidated the involvement of intestinal flora in the pathogenesis of type 2 diabetes mellitus (T2DM) and proposed a novel therapeutic approach targeting intestinal microbes. This advancement enhances our comprehension of the multifaceted and multi-target regulation of T2DM by intestinal microflora, thereby offering fresh avenues for understanding its pathogenesis and clinical management. This letter briefly summarizes the role of intestinal flora in T2DM based on findings from animal experiments and clinical studies. Additionally, it discusses the potential clinical applications and challenges associated with targeting intestinal flora as therapeutic interventions.
糖尿病是一组由多种因素导致高血糖的代谢性疾病。目前糖尿病管理主要侧重于血糖控制，但它本质上是渐进性的，随着时间的推移越来越需要依赖外源性血糖控制方法。因此，迫切需要探索针对糖尿病及其并发症的新型干预策略。人类肠道微生物群通常被称为“第二基因组”，具有显著的多样性，并且在胰岛素抵抗、葡萄糖和脂质代谢以及炎症反应中起关键作用。值得注意的是，李和郭阐明了肠道菌群在2型糖尿病（T2DM）发病机制中的作用，并提出了一种针对肠道微生物的新型治疗方法。这一进展增强了我们对肠道菌群对T2DM多方面、多靶点调节的理解，从而为理解其发病机制和临床管理提供了新途径。本信函基于动物实验和临床研究结果简要总结了肠道菌群在T2DM中的作用。此外，还讨论了将靶向肠道菌群作为治疗干预措施的潜在临床应用及挑战。
